España
Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
2.986 / 17.026
#23883

Re: Farmas USA

impresionante el pipeline, que bonito nombre pipeline, juasjuas....

más me impresiona la caida de hoy, juasjuas... paciencia, tenemos muro de lamentaciones gratis...mejor entrada.

#23884

Re: Farmas USA

No he hecho una buena entrada, pero como tu dices, paciencia y a esperar.-
tiene muy buena pinta esta farma: origen israelita y con coneciones en Alemania y USA; tiene dos trials aprobados en 1º fase FDA y otros tantos iniciándose, así que puede dar mucha guerra este año y el que viene.-
PSTI

#23886

Re: Farmas USA
Prometeo13

Las que os comente hace un tiempo, echarles un ojo.O mejor los dos:

Puma Biotec y Pacira Pharmaceuticals.

Y para los que no querais entrar en dollar hay una pharma que compite con nuestra amada THLD en Francia y es una bestia:

AB SCIENCIES

Hasta el 29/04 no presenta resultados, por lo que conviene seguirla y plantearse un punto de entrada en alguna corrección.Hay tiempo,salvo que haya news de pancreas, entonces fly.

#23887

Re: Farmas USA

DCTH according to this portion of your article this drug could be very significant. A $2 Billion market even if we get only 25% of it for a company with 75M shares out means 500M div 75M = $6.6 dollars per share in new sales that could be huge when translated to the SP. Time being the overriding element. Huge potential though, could be a game changer for the SP. Looking at the current Price/Sales for the TTM it is huge but with this event it could be miniscule by comparison jmho
Article exerpt:
"Delcath Systems' approach is initially targeting the use of melphalan as a chemotherapy agent, which is effective on a broad range of cancers. With sales of approximately $7 billion, the chemotherapy agent is primarily used to treat bigger cancers like liver cancer, colorectal, neuroendocrine or melanomas around the world. However, the company initially sees a $2.3 billion market opportunity driven by multi-histology opportunities in the European Union.

Notably, CHEMOSAT has already been approved in the E.U. and Australia, where it has obtained a CE mark. Initially targeting Italy, Germany, France, the UK, Ireland, the Netherlands and Spain, the company has already completed training in eight E.U. clinical sites. Reimbursement is also progressing with existing programs established in Italy and anticipated programs in Germany and the UK during the first quarter of this year.

An approval on its June 15, 2013 PDUFA date in the U.S. could set the stage for a U.S. launch of CHEMOSAT during the fourth quarter of this year. While the market would be initially limited to ocular melanoma, the company could eventually see the country expand into a multi-billion dollar market of its own. And combined, these markets could unlock significant value in a stock that continues to trade with a market capitalization of just $108 million."[color=red][/color]
http://seekingalpha.com/article/1129091-3-reasons-delcath-systems-appears-undervalued?source=google_news